Bavarian Nordic has signed a manufacturing agreement with the Serum Institute of India (SII), expanding its strategic partnership through an agreement for chikungunya vaccine (CHIKV VLP).
The contract covers the transfer of complete technology for the vaccine production process from Bavarian Nordic to SII, with the aim of increasing production capacity and future supply for low- and middle-income countries.
The new arrangement builds on the existing license and manufacturing partnership between the two companies for the mpox vaccine.
This replaces previous deals with biological E. Both sides will also explore potential joint development opportunities as part of this broader cooperation.
Paul Chaplin, Chairman and CEO of Bavarian Nordic, said: “We are delighted to strengthen our strategic partnership with the Serum Institute of India.
“By leveraging the strengths of both organizations, we can scale up our chikungunya vaccine production to expand global supply and improve access to people around the world.”
CHIKV VLP vaccine is a prepackaged, single-dose, recombinant virus-like particle protein product intended for active immunization against disease caused by chikungunya virus in persons 12 years of age or older.
It is designed to induce a strong seroresponse, with protective immunity beginning to develop as early as one week after vaccination.
Since this virus does not contain genetic material, the vaccine is non-infectious and cannot cause disease, making it suitable for a wide population demographic.
Marketed as Vimkunya, CHIKV VLP has received approval in 2025 from the UK Medicines and Healthcare Products Regulatory Agency (MHRA), the European Commission and the US Food and Drug Administration (FDA).
Regulatory review is underway in Canada and Switzerland.
In September 2025, Bavarian Nordic launched its chikungunya vaccine, Vimconia, in the UK.
The launch followed a significant increase in travel-related illness cases reported across the country. The UK Health Safety Agency (UKHSA) said that incidents increased by 170% in August 2025 compared to the same period in 2024.
“Bavarian Nordic and SII sign agreement to produce chikungunya vaccine” was originally developed and published by Pharmaceutical Technologies, a brand owned by GlobalData.
The information on this site is included in good faith for general information purposes only. It does not amount to advice on which you should rely, and we make no representations, warranties or guarantees, either express or implied, as to its accuracy or completeness. You should obtain professional or expert advice before taking, or refraining from, any action based on the content on our site.
